Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis

Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether el...

Full description

Saved in:
Bibliographic Details
Published inClinical and applied thrombosis/hemostasis Vol. 27; p. 10760296211005555
Main Authors Ahmed, Hafiz Abdul Waqas, Masoud, Ahmed Taher, Han, Jia, Adel Sofy, Ahmed, Saeed Ahmed, Ahmed, Abdesattart, Ahmed Taha, Drokow, Emmanuel Kwateng, Sun, Kai
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 2021
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects
Meta-analysis
Original
Thrombocytopenia
chronic immune thrombocytopenia
thrombopoietin
immune thrombocytopenic purpura
thrombocytopenia
eltrombopag
Online AccessGet full text

Cover

Abstract Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy (“Eltrombopag” OR “Benzoates” OR “Hydrazines”) AND (“Idiopathic Thrombocytopenic Purpura” OR “immune thrombocytopenia” OR “Idiopathic Thrombocytopenic Purpuras” OR “Immune Thrombocytopenia” OR “Autoimmune Thrombocytopenia” OR “Werlhof”). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous (P = .27, I2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous (P = .001, I2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al (P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).
AbstractList Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy (“Eltrombopag” OR “Benzoates” OR “Hydrazines”) AND (“Idiopathic Thrombocytopenic Purpura” OR “immune thrombocytopenia” OR “Idiopathic Thrombocytopenic Purpuras” OR “Immune Thrombocytopenia” OR “Autoimmune Thrombocytopenia” OR “Werlhof”). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous ( P = .27, I 2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous ( P = .001, I 2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al ( P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy (“Eltrombopag” OR “Benzoates” OR “Hydrazines”) AND (“Idiopathic Thrombocytopenic Purpura” OR “immune thrombocytopenia” OR “Idiopathic Thrombocytopenic Purpuras” OR “Immune Thrombocytopenia” OR “Autoimmune Thrombocytopenia” OR “Werlhof”). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous ( P = .27, I 2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous ( P = .001, I 2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al ( P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy (“Eltrombopag” OR “Benzoates” OR “Hydrazines”) AND (“Idiopathic Thrombocytopenic Purpura” OR “immune thrombocytopenia” OR “Idiopathic Thrombocytopenic Purpuras” OR “Immune Thrombocytopenia” OR “Autoimmune Thrombocytopenia” OR “Werlhof”). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous (P = .27, I2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous (P = .001, I2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al (P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy ("Eltrombopag" OR "Benzoates" OR "Hydrazines") AND ("Idiopathic Thrombocytopenic Purpura" OR "immune thrombocytopenia" OR "Idiopathic Thrombocytopenic Purpuras" OR "Immune Thrombocytopenia" OR "Autoimmune Thrombocytopenia" OR "Werlhof"). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], > .0001); pooled results were homogenous ( = .27, I = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], = .003); pooled results were heterogenous ( = .001, I = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al ( = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], = .008).
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy (“Eltrombopag” OR “Benzoates” OR “Hydrazines”) AND (“Idiopathic Thrombocytopenic Purpura” OR “immune thrombocytopenia” OR “Idiopathic Thrombocytopenic Purpuras” OR “Immune Thrombocytopenia” OR “Autoimmune Thrombocytopenia” OR “Werlhof”). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous ( P = .27, I 2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous ( P = .001, I 2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al ( P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy ("Eltrombopag" OR "Benzoates" OR "Hydrazines") AND ("Idiopathic Thrombocytopenic Purpura" OR "immune thrombocytopenia" OR "Idiopathic Thrombocytopenic Purpuras" OR "Immune Thrombocytopenia" OR "Autoimmune Thrombocytopenia" OR "Werlhof"). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous (P = .27, I2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous (P = .001, I2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al (P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy ("Eltrombopag" OR "Benzoates" OR "Hydrazines") AND ("Idiopathic Thrombocytopenic Purpura" OR "immune thrombocytopenia" OR "Idiopathic Thrombocytopenic Purpuras" OR "Immune Thrombocytopenia" OR "Autoimmune Thrombocytopenia" OR "Werlhof"). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous (P = .27, I2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous (P = .001, I2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al (P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).
Author Adel Sofy, Ahmed
Ahmed, Hafiz Abdul Waqas
Han, Jia
Abdesattart, Ahmed Taha
Sun, Kai
Masoud, Ahmed Taher
Drokow, Emmanuel Kwateng
Saeed Ahmed, Ahmed
AuthorAffiliation 3 Kanazawa Medical University, Kanazawa, Japan
1 Department of Hematology, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital Henan, Zhengzhou, People’s Republic of China
2 Faculty of Medicine, Fayoum University, Fayoum, Egypt
AuthorAffiliation_xml – name: 3 Kanazawa Medical University, Kanazawa, Japan
– name: 2 Faculty of Medicine, Fayoum University, Fayoum, Egypt
– name: 1 Department of Hematology, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital Henan, Zhengzhou, People’s Republic of China
Author_xml – sequence: 1
  givenname: Hafiz Abdul Waqas
  orcidid: 0000-0002-5071-8251
  surname: Ahmed
  fullname: Ahmed, Hafiz Abdul Waqas
– sequence: 2
  givenname: Ahmed Taher
  surname: Masoud
  fullname: Masoud, Ahmed Taher
– sequence: 3
  givenname: Jia
  surname: Han
  fullname: Han, Jia
– sequence: 4
  givenname: Ahmed
  surname: Adel Sofy
  fullname: Adel Sofy, Ahmed
– sequence: 5
  givenname: Ahmed
  surname: Saeed Ahmed
  fullname: Saeed Ahmed, Ahmed
– sequence: 6
  givenname: Ahmed Taha
  surname: Abdesattart
  fullname: Abdesattart, Ahmed Taha
– sequence: 7
  givenname: Emmanuel Kwateng
  surname: Drokow
  fullname: Drokow, Emmanuel Kwateng
– sequence: 8
  givenname: Kai
  surname: Sun
  fullname: Sun, Kai
  email: sunkai@cellscience.org
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33874785$$D View this record in MEDLINE/PubMed
BookMark eNp1kkuP0zAUhSM0iHnAD2CDIrGZTQbbiR9hgVRVBSoNYlO2WNfOTesqsYudjtR_jzsdBgaEN7Z8v3N8bN_L4swHj0XxmpIbSqV8R4kUhLWCUUoIz-NZcUHbWlVMsvosr3O9OgLnxWVKW0JoK1rxojivayUbqfhF8X0xTDGMJuxgXS76Hu3k7tBjSiX4rlyFASMYN7jpUDpfzjcxeGfL5TjuPZarzb3WHqawQ-_gfTkrv-AE1czDcEguvSye9zAkfPUwXxXfPi5W88_V7ddPy_nstrK8ZlOFrOecyI5S2hgDkjJODGWma6ySgIqRnhrRN9ChBKgFsZkQ3MqO8YaRtr4qliffLsBW76IbIR50AKfvN0Jca4iTswNqI7JUdUohNg3vaGtq1jbZmvTZvYPs9eHktdubETuLfoowPDF9WvFuo9fhTisiiOTHMNcPBjH82GOa9OiSxWEAj2GfNOM0J-CKNBl9-xe6DfuYHy9TguZgrG7qTNETZWNIKWL_GIYSfewE_U8nZM2bP2_xqPj19Rm4OQEJ1vj72P87_gTplb06
CitedBy_id crossref_primary_10_3390_jcm12123872
crossref_primary_10_1080_14656566_2023_2198089
crossref_primary_10_1159_000529963
Cites_doi 10.1177/2058738419872120
10.1111/bjh.12169
10.3389/fmed.2020.00066
10.1080/09537104.2018.1543864
10.1016/S2352-3026(15)00114-3
10.2165/11207390-000000000-00000
10.1016/S0140-6736(10)60959-2
10.1016/S0140-6736(15)61107-2
10.1080/13696998.2017.1370425
10.1371/journal.pmed.1000097
10.1080/09537104.2019.1572873
10.1182/blood-2003-11-3908
10.2147/CMAR.S213931
10.1002/9781119536604
10.1111/j.1538-7836.2012.04695.x
10.1111/bjh.14380
10.1111/ejh.12725
10.1634/stemcells.2008-0366
10.1016/S0140-6736(09)60402-5
10.1182/blood-2008-07-162503
10.1182/bloodadvances.2019000966
10.1056/NEJMoa073275
10.2217/cer-2019-0177
10.1056/NEJMoa1200931
10.1007/s12185-013-1401-1
10.1177/1076029616663849
10.1111/j.1600-0781.2010.00538.x
10.1592/phco.30.7.666
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021 2021 SAGE Publications Inc. unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021 2021 SAGE Publications Inc. unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1177/10760296211005555
DatabaseName Sage Journals GOLD Open Access 2024
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database

PubMed
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: SAGE Open Access
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1938-2723
ExternalDocumentID oai_doaj_org_article_b62568d88ee445d19b32944ad0fde7da
10_1177_10760296211005555
33874785
10.1177_10760296211005555
Genre Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: No.81471589, No. 81273259
  funderid: https://doi.org/10.13039/501100001809
– fundername: ;
  grantid: No.81471589, No. 81273259
GroupedDBID ---
-MK
01A
0R~
29B
31S
31X
36B
4.4
54M
5GY
5VS
7X7
8FI
8FJ
AAJPV
AAMGE
AARDL
AATBZ
ABAWP
ABHQH
ABJIS
ABQXT
ABUWG
ABVFX
ABXGC
ACARO
ACDXX
ACGFS
ACGZU
ACROE
ACSIQ
ADBBV
ADOGD
AENEX
AERKM
AEUHG
AEUIJ
AEWDL
AEWHI
AFCOW
AFKRA
AFKRG
AFRWT
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ARTOV
AUTPY
AYAKG
B8Z
BDDNI
BENPR
BPHCQ
BSEHC
BVXVI
CCPQU
CS3
DC.
DU5
DV7
EBS
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
HF~
HMCUK
HYE
HZ~
J8X
K.F
M4V
N9A
O9-
OK1
P.B
PIMPY
PQQKQ
Q1R
RIG
ROL
RPM
S01
SFC
SFK
SFT
SGV
SPJ
SV3
UKHRP
-TM
.2F
.2G
1~K
31Y
53G
AACKU
AADTT
AADUE
AAGGD
AAJIQ
AAJOX
AANSI
AAPEO
AAQDB
AAQGT
AAQXH
AARIX
AAXOT
AAYTG
AAZBJ
ABDWY
ABEIX
ABFWQ
ABHKI
ABKRH
ABPGX
ABQKF
ABRHV
ABVVC
ABYTW
ACDSZ
ACFMA
ACFYK
ACGBL
ACLHI
ACOFE
ACSBE
ADEIA
ADGDL
ADMPF
ADNBR
ADTBJ
ADUKL
ADZZY
AECVZ
AEQLS
AEXFG
AEXNY
AFEET
AFKBI
AFUIA
AGNHF
AHHFK
AIGRN
AJABX
AJEFB
AJMMQ
AJSCY
ALJHS
ASPBG
AVWKF
AZFZN
B8M
B8O
B93
BKSCU
CAG
CBRKF
CDWPY
CFDXU
COF
CORYS
CQQTX
CUTAK
DC-
DC0
DD-
DD0
DE-
DOPDO
D~Y
EJD
FEDTE
HVGLF
K.J
NPM
OVD
P.9
Q7K
Q7R
Q7X
Q82
SFB
SFN
SGA
SGP
SGX
SQCSI
TEORI
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
CITATION
H13
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c532t-e2f5507d1114bba71250b12bd4c87ae820f1b6f4ade7aa360c12565c7d2542093
IEDL.DBID RPM
ISSN 1076-0296
1938-2723
IngestDate Thu Jul 04 21:09:15 EDT 2024
Tue Sep 17 21:05:25 EDT 2024
Sat Aug 17 04:09:22 EDT 2024
Fri Sep 13 04:14:35 EDT 2024
Fri Aug 23 02:02:50 EDT 2024
Thu May 23 23:45:03 EDT 2024
Tue Jul 16 20:43:33 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords chronic immune thrombocytopenia
thrombopoietin
immune thrombocytopenic purpura
thrombocytopenia
eltrombopag
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c532t-e2f5507d1114bba71250b12bd4c87ae820f1b6f4ade7aa360c12565c7d2542093
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5071-8251
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060759/
PMID 33874785
PQID 2613292343
PQPubID 4450586
ParticipantIDs doaj_primary_oai_doaj_org_article_b62568d88ee445d19b32944ad0fde7da
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8060759
proquest_miscellaneous_2515685804
proquest_journals_2613292343
crossref_primary_10_1177_10760296211005555
pubmed_primary_33874785
sage_journals_10_1177_10760296211005555
PublicationCentury 2000
PublicationDate 2021-00-00
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021-00-00
PublicationDecade 2020
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: United States
– name: Thousand Oaks
– name: Sage CA: Los Angeles, CA
PublicationTitle Clinical and applied thrombosis/hemostasis
PublicationTitleAlternate Clin Appl Thromb Hemost
PublicationYear 2021
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: SAGE Publishing
References Yang, Lin, Yao, Ji, Shen 2019; 24
Grainger, Locatelli, Chotsampancharoen 2015; 386
Neunert, Terrell, Arnold 2019; 3
Cheng, Saleh, Marcher 2011; 377
Higgins, Thomas, Chandler 2019
Yang, Li, Jin 2017; 176
Giordano, Lassandro, Barone 2020; 7
Shi, Xu, Yang 2019; 11
Olnes, Scheinberg, Calvo 2012; 367
Bowen, Lobb, Park, Sanderson, Ferguson 2010; 26
Erickson-Miller, Delorme, Tian 2009; 27
Forsythe, Schneider, Pham 2020; 9
Katsutani, Tomiyama, Kimura 2013; 98
Bussel, De Miguel, Despotovic 2015; 2
Bussel, Saleh, Vasey, Mayer, Arning, Stone 2013; 160
Bussel, Cheng, Saleh 2007; 357
Nakhoul, Kozuch, Varma 2006; 4
Çekdemir, Güvenç, Özdemirkıran 2019; 36
González-López, Alvarez-Román, Pascual 2016; 97
Chouhan, Herrington 2010; 30
Bussel, Provan, Shamsi 2009; 373
Cheng, Yan, Ma 2019; 33
Donga, Bilir, Little, Babinchak, Munakata 2017; 20
Saleh, Bussel, Cheng 2013; 19
Garnock-Jones 2011; 71
Arai, Matsui, Jo, Kondo, Takaori-Kondo 2019; 30
Tomiyama, Miyakawa, Okamoto 2012; 10
McMillan, Durette 2004; 104
Rodeghiero, Stasi, Gernsheimer 2009; 113
Moher, Liberati, Tetzlaff, Altman 2009; 6
Elgebaly, Ashal, Elfil, Menshawy 2017; 23
Tumaini Massaro, Chen, Ke 2019; 30
bibr5-10760296211005555
bibr2-10760296211005555
bibr30-10760296211005555
Yang R (bibr33-10760296211005555) 2019; 24
bibr15-10760296211005555
bibr10-10760296211005555
bibr8-10760296211005555
bibr18-10760296211005555
bibr28-10760296211005555
bibr7-10760296211005555
Saleh MN (bibr25-10760296211005555) 2013; 19
bibr14-10760296211005555
bibr1-10760296211005555
bibr4-10760296211005555
bibr31-10760296211005555
bibr21-10760296211005555
bibr11-10760296211005555
bibr24-10760296211005555
bibr9-10760296211005555
bibr32-10760296211005555
bibr29-10760296211005555
bibr22-10760296211005555
Nakhoul IN (bibr27-10760296211005555) 2006; 4
bibr19-10760296211005555
bibr3-10760296211005555
bibr13-10760296211005555
bibr23-10760296211005555
bibr26-10760296211005555
bibr6-10760296211005555
bibr16-10760296211005555
Çekdemir D (bibr17-10760296211005555) 2019; 36
Forsythe A (bibr20-10760296211005555) 2020; 9
References_xml – volume: 160
  start-page: 538
  issue: 4
  year: 2013
  end-page: 546
  article-title: Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)
  publication-title: Brit J Haematol
  contributor:
    fullname: Stone
– volume: 20
  start-page: 1200
  issue: 11
  year: 2017
  end-page: 1206
  article-title: Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura
  publication-title: J Med Econ
  contributor:
    fullname: Munakata
– volume: 7
  start-page: 1
  year: 2020
  end-page: 7
  article-title: Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)
  publication-title: Front Med
  contributor:
    fullname: Barone
– volume: 104
  start-page: 956
  issue: 4
  year: 2004
  end-page: 960
  article-title: Long-term outcomes in adults with chronic ITP after splenectomy failure
  publication-title: Blood
  contributor:
    fullname: Durette
– volume: 10
  start-page: 799
  issue: 5
  year: 2012
  end-page: 806
  article-title: A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia
  publication-title: J Thromb Haemost
  contributor:
    fullname: Okamoto
– volume: 2
  start-page: e315
  issue: 8
  year: 2015
  end-page: 325
  article-title: Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study
  publication-title: Lancet Haematol
  contributor:
    fullname: Despotovic
– volume: 24
  start-page: 290
  issue: 1
  year: 2019
  end-page: 299
  article-title: Therapeutic options for adult patients with previously treated immune thrombocytopenia—a systematic review and network meta-analysis
  publication-title: Hematology (United Kingdom)
  contributor:
    fullname: Shen
– volume: 30
  start-page: 828
  issue: 7
  year: 2019
  end-page: 835
  article-title: Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis
  publication-title: Platelets
  contributor:
    fullname: Ke
– volume: 30
  start-page: 946
  issue: 8
  year: 2019
  end-page: 956
  article-title: Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis
  publication-title: Platelets
  contributor:
    fullname: Takaori-Kondo
– volume: 4
  start-page: 136
  issue: 2
  year: 2006
  end-page: 144
  article-title: Management of adult idiopathic thrombocytopenic purpura
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: Varma
– volume: 71
  start-page: 1333
  issue: 10
  year: 2011
  end-page: 1353
  article-title: Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia
  publication-title: Drugs
  contributor:
    fullname: Garnock-Jones
– volume: 367
  start-page: 11
  issue: 1
  year: 2012
  end-page: 19
  article-title: Eltrombopag and improved hematopoiesis in refractory aplastic anemia
  publication-title: New Engl J Med
  contributor:
    fullname: Calvo
– volume: 97
  start-page: 297
  issue: 3
  year: 2016
  end-page: 302
  article-title: Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
  publication-title: Eur J Haematol
  contributor:
    fullname: Pascual
– volume: 19
  start-page: 191
  issue: 2
  year: 2013
  article-title: Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
  publication-title: Transfuze a Hematologie Dnes
  contributor:
    fullname: Cheng
– volume: 27
  start-page: 424
  issue: 2
  year: 2009
  end-page: 430
  article-title: Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist
  publication-title: Stem Cell
  contributor:
    fullname: Tian
– volume: 3
  start-page: 3829
  issue: 23
  year: 2019
  end-page: 3866
  article-title: American Society of Hematology 2019 guidelines for immune thrombocytopenia
  publication-title: Blood Adv
  contributor:
    fullname: Arnold
– volume: 98
  start-page: 323
  issue: 3
  year: 2013
  end-page: 330
  article-title: Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study
  publication-title: Int J Hematol
  contributor:
    fullname: Kimura
– volume: 11
  start-page: 8229
  year: 2019
  end-page: 8238
  article-title: The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
  publication-title: Cancer Manag Res
  contributor:
    fullname: Yang
– volume: 176
  start-page: 101
  issue: 1
  year: 2017
  end-page: 110
  article-title: Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia
  publication-title: Brit J Haematol
  contributor:
    fullname: Jin
– volume: 386
  start-page: 1649
  issue: 10004
  year: 2015
  end-page: 1658
  article-title: Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
  publication-title: The Lancet
  contributor:
    fullname: Chotsampancharoen
– volume: 26
  start-page: 243
  issue: 5
  year: 2010
  end-page: 249
  article-title: Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial
  publication-title: Photodermatol Photoimmunol Photomed
  contributor:
    fullname: Ferguson
– volume: 23
  start-page: 928
  issue: 8
  year: 2017
  end-page: 937
  article-title: Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials
  publication-title: Clin Appl Thromb Hemost
  contributor:
    fullname: Menshawy
– volume: 377
  start-page: 393
  issue: 9763
  year: 2011
  end-page: 402
  article-title: Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
  publication-title: Lancet
  contributor:
    fullname: Marcher
– volume: 9
  start-page: 447
  issue: 7
  year: 2020
  end-page: 457
  article-title: Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists
  publication-title: J Comp Eff Res
  contributor:
    fullname: Pham
– volume: 113
  start-page: 2386
  issue: 11
  year: 2009
  end-page: 2393
  article-title: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an International Working Group
  publication-title: Blood
  contributor:
    fullname: Gernsheimer
– volume: 373
  start-page: 641
  issue: 9664
  year: 2009
  end-page: 648
  article-title: Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
  publication-title: The Lancet
  contributor:
    fullname: Shamsi
– volume: 33
  start-page: 1
  year: 2019
  end-page: 7
  article-title: Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: a single-center observational study
  publication-title: Int J Immunopathol Pharmacol
  contributor:
    fullname: Ma
– volume: 357
  start-page: 2237
  issue: 22
  year: 2007
  end-page: 2247
  article-title: Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
  publication-title: New Engl J Med
  contributor:
    fullname: Saleh
– volume: 36
  start-page: 230
  issue: 4
  year: 2019
  end-page: 237
  article-title: A multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: a real-life experience
  publication-title: Turk J Hematol
  contributor:
    fullname: Özdemirkıran
– volume: 6
  start-page: e1000097
  issue: 7
  year: 2009
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: PLoS Med
  contributor:
    fullname: Altman
– volume: 30
  start-page: 666
  issue: 7
  year: 2010
  end-page: 683
  article-title: Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag
  publication-title: Pharmacotherapy
  contributor:
    fullname: Herrington
– year: 2019
  publication-title: Cochrane Handbook for Systematic Reviews of Interventions
  contributor:
    fullname: Chandler
– ident: bibr18-10760296211005555
  doi: 10.1177/2058738419872120
– volume: 19
  start-page: 191
  issue: 2
  year: 2013
  ident: bibr25-10760296211005555
  publication-title: Transfuze a Hematologie Dnes
  contributor:
    fullname: Saleh MN
– volume: 4
  start-page: 136
  issue: 2
  year: 2006
  ident: bibr27-10760296211005555
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: Nakhoul IN
– ident: bibr16-10760296211005555
  doi: 10.1111/bjh.12169
– ident: bibr21-10760296211005555
  doi: 10.3389/fmed.2020.00066
– ident: bibr32-10760296211005555
  doi: 10.1080/09537104.2018.1543864
– ident: bibr14-10760296211005555
  doi: 10.1016/S2352-3026(15)00114-3
– ident: bibr30-10760296211005555
  doi: 10.2165/11207390-000000000-00000
– ident: bibr4-10760296211005555
  doi: 10.1016/S0140-6736(10)60959-2
– ident: bibr23-10760296211005555
  doi: 10.1016/S0140-6736(15)61107-2
– ident: bibr19-10760296211005555
  doi: 10.1080/13696998.2017.1370425
– ident: bibr10-10760296211005555
  doi: 10.1371/journal.pmed.1000097
– ident: bibr31-10760296211005555
  doi: 10.1080/09537104.2019.1572873
– ident: bibr5-10760296211005555
  doi: 10.1182/blood-2003-11-3908
– ident: bibr7-10760296211005555
  doi: 10.2147/CMAR.S213931
– ident: bibr11-10760296211005555
  doi: 10.1002/9781119536604
– ident: bibr6-10760296211005555
  doi: 10.1111/j.1538-7836.2012.04695.x
– volume: 24
  start-page: 290
  issue: 1
  year: 2019
  ident: bibr33-10760296211005555
  publication-title: Hematology (United Kingdom)
  contributor:
    fullname: Yang R
– ident: bibr26-10760296211005555
  doi: 10.1111/bjh.14380
– ident: bibr22-10760296211005555
  doi: 10.1111/ejh.12725
– ident: bibr28-10760296211005555
  doi: 10.1634/stemcells.2008-0366
– ident: bibr15-10760296211005555
  doi: 10.1016/S0140-6736(09)60402-5
– ident: bibr1-10760296211005555
  doi: 10.1182/blood-2008-07-162503
– ident: bibr3-10760296211005555
  doi: 10.1182/bloodadvances.2019000966
– ident: bibr2-10760296211005555
  doi: 10.1056/NEJMoa073275
– volume: 9
  start-page: 447
  issue: 7
  year: 2020
  ident: bibr20-10760296211005555
  publication-title: J Comp Eff Res
  doi: 10.2217/cer-2019-0177
  contributor:
    fullname: Forsythe A
– ident: bibr8-10760296211005555
  doi: 10.1056/NEJMoa1200931
– volume: 36
  start-page: 230
  issue: 4
  year: 2019
  ident: bibr17-10760296211005555
  publication-title: Turk J Hematol
  contributor:
    fullname: Çekdemir D
– ident: bibr24-10760296211005555
  doi: 10.1007/s12185-013-1401-1
– ident: bibr9-10760296211005555
  doi: 10.1177/1076029616663849
– ident: bibr13-10760296211005555
  doi: 10.1111/j.1600-0781.2010.00538.x
– ident: bibr29-10760296211005555
  doi: 10.1592/phco.30.7.666
SSID ssj0019696
Score 2.2992203
Snippet Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of...
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 10760296211005555
SubjectTerms Meta-analysis
Original
Thrombocytopenia
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3BbtQwEB2hHlAviLZQAi0yEgKpUkTs2I7T24JaFaRy2ko9EdmxQ1dqs2hJD_v3nXG8264K4sI1dqLRzNh-k5l5BniveKD-Rp8L6lOWrra50d7m3AQhjcQzp4sFst_12YX8dqkuH1z1RTVhIz3wqLhPDgG6Nt6YEKRUnteuFLWU1hedD5UfoRFXq2Aq5Q-I8yXlMHlsLq90IWpN0Q4xXKmNUyiS9f8JYT4ulHxQ7RUPoNPn8CwhRzYZJd6BJ6Hfhb1Jj1HzzZJ9YLGWM_4k34Wn5yllvgc_Tq6HxfyGqkd-spGrOG1wzPaeTefXYTFydS_ZrGeJLJd9pb6RwKZX8d12OdA1WzN7zCbsPAw2X5GZvICL05Ppl7M8XaqQt6oUQx5ERxRmHvc46ZytEOAUjgvnZWsqG8g43OkOFRwqa0tdtDhDq7byGEqKoi5fwlY_78MrYAh1ualbxXXrZUfpZBVwTxBlhR-ohcjgaKXk5tfIndHwRC_-yCIZfCYzrCcS7XV8gM7QJGdo_uUMGRysjNiktfi7wRgRZ4lSlhm8Ww_jKqLUiO3D_BbnIKwjJv5CZrA_2nwtCQbxdMkASlhteMOGqJsj_ewqMnWbQiMkqzP4SH5zL9JftfD6f2jhDWwLqryJP4oOYGtY3IZDhE6DextXyR1DZRHd
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9wwDBddC2MvY2v3kbUbHowNBuFix3GSvYzruHIbtIxxhT4t2LHTHrRJd00f7r-f5PiuO7rtNXaCYsmyZEk_AbzLuKP6RhsLqlOWptRxoayOeeGELCSeOY1PkD1R01P57Sw724LpqhaG0ipXOtEratvVdEc-Qks_FWiNyHSkDd0C1P3o8_WvmPpHUZw1NNN4ADuCSwrY7hxOTr7_WEcUCAVmyD-kpNtShQgn96XnuaJH5AsR_lW2cUZ5KP-_2Z_30yj_yAXzx9PRE3gc7Eo2HgThKWy5dhf2xi361FdL9p75TE9_hb4LD49DQH0Pfk4u-0V3Rbkl52xAMg7qj-nWsll36RYDkveSzVsWoHTZV6oqcWx24d-tlz014ZrrT2zMjl2v4xXUyTM4PZrMvkzj0HIhrrNU9LETDQGcWdSA0hido_mTGC6MlXWRa0es40Y1UluXa52qpMYZKqtzi46mSMr0OWy3XeteAkNDmBdlnXFVW9lQsDlzqDFEmuMHSiEi-Lha5Op6QNaoeAAfv8eRCA6JDeuJBIrtH3SL8yrsscqgL6cKWxTOSZlZXhqUGIm0Jg2Sa3UEBysmVmGn3lR3chXB2_Uw7jEKnOjWdbc4B40-wulPZAQvBp6vKUEXn1oQIIX5hjRskLo50s4vPI53kSg02MoIPpDc3JH0z1V49f8f2IdHgjJu_AXRAWz3i1v3Gk2m3rwJu-E3b9UPuA
  priority: 102
  providerName: ProQuest
– databaseName: Sage Journals GOLD Open Access 2024
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Rb9MwED6NTUK8INiAZQxkJAQSUiCxHcfhraBVA2k8oE7siciJna3SmqAufei_585xCtWGxFOl5NqefD77zvfdZ4DXWeqov9HGnPqUZVWYWCtr4lQ7LrXEPafxANlv6vRcfr3ILnagG3thwgjevCdYFWrkF2vybjqN_hCKjPiZq4QXirIXYqzClL5flMNx93irBj2h-vRqQaXtmgCR63hsb7sHexyTP3SJvcn0-4_ZpvBAZDEDTJGwuYUKhdA7_3RrK_OM_3eFqbfRln9BxvwuNn0ED0P4ySbDfHkMO67dh4NJi6n3Ys3eMA8I9Sft-3D_LNTdD-DnyXW_7BYEQblkA-FxWCWZaS2bddduORB-r9m8ZYFxl32h5hPHZlf-u_W6p7u65uYjm7Az15t4ZER5AufTk9nn0zjczBDXmeB97HhDPGgWF0pZVSbHKCmpUl5ZWevcOLJwWqlGGutyY4RKapRQWZ1bzEd5UoinsNt2rTsEhvFyqos6S1VtZUM16czhwsJFjj9QcB7Bu3GQy18DAUeZBo7yWxaJ4BOZYSNI3Nn-Qbe8LIMrlhWmfEpbrZ2TMrNpUQleSNQ1aVBdayI4Ho1YjtOxxEQTpbiQIoJXm9foilRfMa3rViiDsSHR-ScygmeDzTeaCKHppgLUMN-aDVuqbr9p51ee7lsnCuO6IoK3NG_-qPTPUTj6b8nn8IATRscfKR3Dbr9cuRcYZPXVy-AYvwFp_B46
  priority: 102
  providerName: SAGE Publications
Title Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis
URI https://journals.sagepub.com/doi/full/10.1177/10760296211005555
https://www.ncbi.nlm.nih.gov/pubmed/33874785
https://www.proquest.com/docview/2613292343/abstract/
https://www.proquest.com/docview/2515685804/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC8060759
https://doaj.org/article/b62568d88ee445d19b32944ad0fde7da
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDsZextbuw1sXNBgbDNzYsvy1t7QkdIOUUlKWpxnJkttAYpfMfch_vztZzha6vezJYMv2oTtJd7rf_QTwIQ4N1Tdqn1OdslC59LNESz_MDBeZwDWnsgDZi-T8Wnybx_M9iPtaGAvaL9XipF6uTurFrcVW3q3KYY8TG15Oz7IgwZUuH-7DfhpFfYjuUgdE99IBDQldmyculRnaGvM0oVsU9BDRFR1bgyEaUcjHO-uSpe__m8_5EDr5B_7LLkmTZ_DU-ZJs1Mn8HPZMfQhHoxrj6NWGfWQW3Wm3zQ_h8dQl0Y_gx3jZrpsV4UluWMde7KY8JmvNZs3SrDv27g1b1MzR57KvVEli2OzWvltuWjp4ayG_sBGbmlb6Pb3JC7iejGdn5747ZsEv44i3vuEVkZppnPWEUjJFlydQIVdalFkqDakrVEklpDaplFESlNgiictUY3DJgzx6CQd1U5vXwND5DbO8jMOk1KKiBHNscJbgUYofyDn34HPfycVdx6ZRhI5w_IFyPDglNWwbEhG2vdGsbwpnDoXC-C3JdJYZI0Ssw1xFPBcoa1ChuFp6cNwrsXCj82eBUSO24pGIPHi_fYzjipIlsjbNPbZBR4-4-QPhwatO51tJepvxIN2xhh1Rd5-gKVvubme6Hnwiu_kt0j974c1__-MtPOEEwLH7Rcdw0K7vzTv0oFo1wHEzTwfwaDS5-j7D6-n44vJqYPcjBnY0_QJQLxjP
link.rule.ids 230,315,733,786,790,870,891,2115,4043,12083,21416,21994,27886,27956,27957,27958,31754,31755,33779,33780,43345,43840,44980,45368,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwED7BkIAXBBs_AgOMhEBCihY7jpPwggra1MG6p07qE5EdO1ulLRld9tD_njvH7agGvMZOdPHZ5zvf5-8A3mfc0f1GGwu6pyxNqeNCWR3zwglZSNxzGg-QPVbjE_l9ls3CgdtVgFWubKI31Lar6Yx8Dz39VKA3ItMvl79iqhpF2dVQQuMu3JNpKgnSl8_WAZdnfhkwhwS0LVXIanJ_3TxX9IjiH-K8yjb2JU_f_zef8zZ08g_8l9-SDh7Do-BLstGg_Cdwx7XbsDNqMY6-WLIPzKM7_bH5NtyfhCT6DvzcP-8X3QXhSU7ZwF4cTB7TrWXT7twtBvbuJZu3LNDnskO6SeLY9My_Wy97Krw115_ZiE1cr-MVvclTODnYn34bx6HMQlxnqehjJxoiNbNo9aQxOkeXJzFcGCvrIteO1MWNaqS2Ltc6VUmNPVRW5xaDS5GU6TPYarvWvQCGzi8vyjrjqrayoQRz5tBKiDTHD5RCRPBpNcjV5cCmUfFAOH5LIxF8JTWsOxIRtn_QLU6rsK4qg_GbKmxROCdlZnlpcJZIlDVpUFyrI9hdKbEKq_OquplLEbxbN-O6omSJbl13jX3Q0SNu_kRG8HzQ-VoSDOup7ABKmG_Mhg1RN1va-Znn7i4ShU5aGcFHmjc3Iv1zFF7-_wfewoPxdHJUHR0e_3gFDwUhbvwB0S5s9Ytr9xpdpt688eviN5HMDYU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_BkCZe-Nj4CAwwEgIJKW3iOF-8lbFpAzrtoZMmHojs2Nkq2rQq6UP567lznLIyeNlrfEnO9tm-8_38M8CbODR0vlH7nM4pC5VLP0u09MPMcJEJXHMqC5A9SY7OxOfz-PzKVV8WtF-qca-eTHv1-NJiK-fTst_hxPqnw_0sSHCly_tzXfVvwx0cszzvAnWXQCDSlxZuSBjbPHEJzdCeNE8TekShD9Fd0eU1GKgRkXy8sTpZEv9_eZ7XAZRXUGB2YTq8D9-6KrV4lB-9ZaN65a-_2B5vVOcHcM-5q2zQijyEW6begd1BjaH6dMXeMgsgtTvzO7A9dHn6Xfh-MGkWsylBVi5YS5DsZlUma81Gs4lZtAThKzaumWPoZcd0WMWw0aV9t1w1dLfXWH5gAzY0jfQ7BpVHcHZ4MNo_8t1NDn4ZR7zxDa-IN03jxCqUkil6VYEKudKizFJpyCJClVRCapNKGSVBiRJJXKYa41ce5NFj2KpntXkKDP3rMMvLOExKLSrKYccGJyIepfiBnHMP3nc9WMxbwo4idJzm13reg4_Ux2tB4tq2D2aLi8K1fqEwREwynWXGCBHrMFcRzwXqGlSorpYe7HUWUrgJ4GeBgSlK8UhEHrxeF-PQpXyMrM1siTLoSxL9fyA8eNIa1FqTziA9SDdMbUPVzRK0HEsP7izFg3dklH9U-m8rPLvxP17B9umnw-Lr8cmX53CXE9zH7k7twVazWJoX6K816qUdmb8BuYU4LQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Eltrombopag+Effectiveness+and+Tolerability+in+Chronic+Immune+Thrombocytopenia%3A+A+Meta-Analysis&rft.jtitle=Clinical+and+applied+thrombosis%2Fhemostasis&rft.au=Ahmed%2C+Hafiz+Abdul+Waqas&rft.au=Masoud%2C+Ahmed+Taher&rft.au=Han%2C+Jia&rft.au=Adel+Sofy%2C+Ahmed&rft.date=2021&rft.eissn=1938-2723&rft.volume=27&rft.spage=10760296211005555&rft_id=info:doi/10.1177%2F10760296211005555&rft_id=info%3Apmid%2F33874785&rft.externalDocID=33874785
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1076-0296&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1076-0296&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1076-0296&client=summon